Anavex Life Sciences Corp (AVXL): Topline data U.S. Phase 2 RTT

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	137
Posts	22868
Boards Moderated	0
Alias Born	04/08/2004

georgejjl

Re: None

Thursday, 11/26/2020 11:06:27 AM

Thursday, November 26, 2020 11:06:27 AM

Topline data U.S. Phase 2 RTT – Q4 2020

https://www.anavex.com/wp-content/uploads/2020/11/Anavex-Presentation-November-2020.pdf

ANAVEX®2-73-PDD-001 Study: Next Steps
• These results support continued development in PDD / PD as well as the currently ongoing
Phase 2 and Phase 2/3 clinical studies with ANAVEX®2-73 (blarcamesine) in Rett syndrome1
and Alzheimer’s disease2
• Data of cognitive domain improvements highly relevant for broader dementia indications,
including Alzheimer’s disease
• Complete data analysis, including MDS-UPDRS, actigraphy (24-hour monitoring), entire DNA
and RNA sequencing, ongoing
• ANAVEX®2-73-PDD-EP-001 48-week open-label extension (OLE) study ongoing, which
continues to assess safety, long term efficacy and changes in gut microbiota3
• Data will be submitted to the U.S. Food and Drug Administration to seek regulatory guidance

https://www.anavex.com/wp-content/uploads/2020/11/CTAD-Anavex-PDD-001-Topline-data-Presentation-2020.pdf

Good luck and GOD bless,